Osteonecrosis of the Jaw Associated with Long-Term Denosumab Therapy: Three Case Reports
Year: 2025
Type: article
Abstract: Background: Denosumab, a monoclonal antibody against RANKL, is used at high dose for skeletal-related events in oncology andat low dose for osteoporosis, but both regimens carry a risk of medication-related osteonecrosis of the jaw (MRONJ).Objective: To review published case reports/series and the epidemiologic, mechanistic and guideline literature ondenosumab-associated MRONJ, contrasting oncologic and osteoporosis populations.Methods: Narrative review of case reports, case series, randomized trials, retrospective cohorts, and guidelines.Findings: Pooled oncology-trial data show MRONJ in 1.8% of denosumab-treated versus 1.3% of zoledronic acid-treated patients;a 20-year breast cancer cohort found 12% incidence with denosumab versus 3% with bisphosphonates. Published cases spanmulti-year high-dose oncologic exposure to osteoporosis patients developing MRONJ after a single low dose, oftenextraction-triggered. Unlike bisphosphonates, denosumab's effect is reversible, informing but not resolving the drug-holidaydebate.Conclusions: Pre-therapy dental screening, AAOMS-staged diagnosis, and conservative-first management with surgery reservedfor refractory disease remain the evidence base; drug holidays lack proven benefit.
Authors: Kubik K, Baumann U, Sousa B
Language: English
Topic: Bone health and treatments
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7208816031
